Horizon Discovery Group plc Director/PDMR Shareholding (4032P)

TIDMHZD

RNS Number : 4032P

Horizon Discovery Group plc

07 February 2019

Horizon Discovery Group plc

7 February 2019

Horizon Discovery Group plc

Director/PDMR Shareholding

Cambridge, UK, 7 February 2019: Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Group" or "the Company"), a global leader in gene editing and gene modulation technologies, announces that the following options were granted on 6 February 2019 over the Company's ordinary shares of 1 pence each ("Ordinary Shares") to Jayesh Pankhania, CFO, in accordance with the Company's Long Term Incentive Plan:

 
 Director           Number of Ordinary   Exercise price per 
                     Shares over which    share 
                     options granted 
 Jayesh Pankhania   45,064               GBP0.01 
                   -------------------  ------------------- 
 Jayesh Pankhania   128,755              GBP1.7475 
                   -------------------  ------------------- 
 

The options with a GBP0.01 exercise price will vest equally on each of the second, third and fourth anniversaries of the grant date.

The options with a GBP1.7475 exercise price will vest 25% on the third anniversary of the grant date, 25% on the fourth anniversary of the grant date and 50% on the fifth anniversary of the grant date.

The options granted are equivalent to 0.116% of the Company's existing issued share capital.

ENDS

For further information from Horizon Discovery Group plc, please contact:

Horizon Discovery Group plc

Terry Pizzie, Chief Executive Officer

Jayesh Pankhania, Chief Financial Officer

Tel: [phone]

Numis Securities Limited (Broker and NOMAD)

Michael Meade / Freddie Barnfield / Duncan Monteith

Tel: [phone]

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott / Matthew Neal / Melissa Gardiner

Tel: [phone]

Email: [e-mail]

About Horizon Discovery Group plc www.horizondiscovery.com

Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world leader in gene editing and gene modulation technologies. Horizon designs and engineers cells using its translational genomics platform, a highly precise and flexible suite of DNA editing tools (rAAV, ZFN, CRISPR and Transposon) and, following the acquisition of Dharmacon, Inc., its functional genomics platform comprising gene knockdown (RNAi) and gene expression (cDNA, ORF) tools, for research and clinical applications that advance human health. Horizon's platforms and capabilities enable researchers to alter almost any gene or modulate its function in human or mammalian cell-lines.

Horizon offers an extensive range of catalogue products and related research services to support a greater understanding of the function of genes across all species and the genetic drivers of human disease and the development of personalised molecular, cell and gene therapies. These have been adopted by over 10,000 academic, drug discovery, drug manufacturing and clinical diagnostics customers around the globe, as well as in the Company's own R&D pipeline.

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange's AIM market under the ticker "HZD".

 
 1     Details of the person discharging managerial responsibilities/person 
        closely associated 
 a)    Name                                    Jayesh Pankhania 
      --------------------------------------  ----------------------------------- 
 2     Reason for the notification 
      --------------------------------------------------------------------------- 
 a)    Position/status                         Chief Financial Officer - PDMR 
      --------------------------------------  ----------------------------------- 
 b)    Initial notification /Amendment         Initial Notification 
      --------------------------------------  ----------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      --------------------------------------------------------------------------- 
 a)    Name                                    Horizon Discovery Group plc 
      --------------------------------------  ----------------------------------- 
 b)    Legal Entity Identifier                 213800L812B9NI5M3G89 
      --------------------------------------  ----------------------------------- 
 4     Details of the transaction(s): section to be repeated for 
        (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      --------------------------------------------------------------------------- 
 a)    Description of the financial            Options over ordinary shares 
        instrument, type of instrument          of 1.0 pence each 
        Identification code 
                                                GB00BK8FL363 
      --------------------------------------  ----------------------------------- 
 b)    Nature of the transaction               Grant of Options 
      --------------------------------------  ----------------------------------- 
 c)    Currency                                GBP 
      --------------------------------------  ----------------------------------- 
 d)    Price(s) and volume(s)                   Exercise Price     No. of shares 
      --------------------------------------  ------------------  --------------- 
                              GBP0.01                                  45,064 
  --------------------------------------------------------------  --------------- 
                             GBP1.7475                                128,755 
  --------------------------------------------------------------  --------------- 
 
 e)    Aggregated information 
        - Aggregated volume 
        - Price                                  n/a 
        - Aggregated total 
      --------------------------------------  ----------------------------------- 
 f)    Date of the transaction                 6 February 2019 
      --------------------------------------  ----------------------------------- 
 g)    Place of the transaction                Off market 
      --------------------------------------  ----------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHLDLFBKLFLBBB

(END) Dow Jones Newswires

February 07, 2019 07:22 ET (12:22 GMT)